Apolipoprotein (apo) E5 is a rare apoE isoform. The apoE5 (Glu3Lys) variant, which is caused by the substitution of lysine with glutamic acid at codon 3, has a relative frequency of 0.1% in Japan. Previous studies have reported that apoE5 (Glu3Lys) is associated with hyperlipidemia and cardiovascular diseases, but this isoform has higher LDL receptor-binding activity than that of normal apoE3. Nephropathy associated with apoE5 (Glu3Lys) alone has not yet been reported. We present a case of a 51-year-old man with nephrotic syndrome. On renal biopsy, three glomeruli showed segmental sclerosis with hypertrophy of podocytes and intracapillary marked infiltration of intraglomerular foam cells. These findings were compatible with focal segmental glomerulosclerosis (FSGS). The patient had mild diabetes mellitus and monoclonal gammopathy of undetermined significance, but there were no specific findings of nephrolopathy related to these diseases. Various factors are involved in the pathogenesis of FSGS, including dyslipidemia and apoE activity. Our findings suggest that abnormal lipid metabolism by ApoE5 (Glu3Lys) is involved in the onset of FSGS.
Introduction
Human apolipoprotein (apo) E is a glycoprotein of 34 kD containing 299 amino acids; it forms a lipoprotein with triglycerides and cholesterol and plays a central role in lipoprotein metabolism. ApoE has three major isoforms, i.e., apoE2, E3, and E4, and three minor isoforms (E1, E5, and E7) have also been reported. In Japan, an apoE5 variant caused by the substitution of lysine to glutamic acid at codon 3 has been observed, with a relative frequency of approximately 0.1% [1] .
Previous studies have shown that apoE5 (Glu3Lys) is involved in hyperlipoproteinemia and cardiovascular diseases, although this isoform has higher LDL receptorbinding activity than that of normal apoE3 [2, 3] . Hyperlipidemic kidney disease is related to apoE5, and several cases of lipoprotein glomerulopathy (LPG) have recently been reported. However, other mutations specific to LPG, such as apoE-Chicago [4] and apoE-Sendai [5] , have been detected in these cases and therefore the causative role of apoE5 is not clear.
We report a case of hyperlipidemic focal segmental glomerulosclerosis (FSGS) associated with heterozygous apoE5 (Glu3Lys) and wild-type apoE3. A variety of factors are implicated in the pathogenesis of FSGS [6] , including roles of dyslipidemia [7] and apoE [8] , and abnormal lipid metabolism by ApoE5 (Glu3Lys) may be involved in the onset of FSGS, as observed in this case.
Case report
A 51-year-old Japanese man was admitted to Fukuoka University Hospital for the examination of kidney disease. He had been treated for hypertension, diabetes, dyslipidemia, and hypothyroidism for 15 years by a local practitioner, and nephrotic syndrome was suspected based on hypoproteinemia and leg edema 10 months before transfer. Although he had a past history of diabetes mellitus since approximately 10 years, he took an oral hypoglycemin agent, and findings of diabetic retinopathy and neuropathy were lacking. In addition, there was no family history of diabetes, dyslipidemia, or kidney diseases.
On admission, the patient exhibited a height of 174 cm, weight of 78.9 kg, and blood pressure of 184/105 mmHg. Physical examination revealed no particular abnormalities, other than pitting edema of the lower extremities. Systemic manifestations characteristic of lipidosis, such as corneal arcus and xanthoma, were not recognized. Laboratory findings were as follows: white blood cell count, 6,600/ µL (neutrophils, 76.7%; lymphocytes, 18.6%; eosinophils, 0.3%); hemoglobin, 14.0 g/dL; platelet count, 227,000/ µL; total protein, 5.3 g/dL; albumin, 2.5 g/dL; fasting blood glucose 102 mg/dL; hemoglobin A1c, 6.0%; creatinine, 1.06 mg/dL; urea nitrogen, 18 mg/dL; triglycerides, 141 mg/dL; low-density lipoprotein cholesterol, 208 mg/ dL; high-density lipoprotein cholesterol, 81 mg/dL. Liver function was within normal ranges. Serum immunoglobulin and complement levels were as follows: IgG, 701 mg/ dL; IgA, 182 mg/dL; IgM, 44 mg/dL; C3, 160 mg/dL; C4, 47 mg/dL. Results for anti-nuclear antibodies were negative. The serum apoE level was 5.7 mg/dL (normal range 2.7-4.3 mg/dL). A lipoprotein analysis by agarose gel electrophoresis showed a pattern consistent with type IIa hyperlipoproteinemia, with a slight elevation of the preβ band. Urinalysis showed substantial protein excretion (12.4 g/gCr) and mild hematuria in sediments (red blood cells 5-9/hpf).
An M-spike was detected by serum protein electrophoresis, and serum immunoelectrophoresis showed an M-bow of IgG-κ type. Bone marrow aspiration and biopsy revealed 3% plasma cells with normal cytogenesis. The skeletal survey was negative for lytic lesions or pathological fractures. Based on these findings, the patient was diagnosed with monoclonal gammopathy of undetermined significance (MGUS).
Pathological findings
The patient underwent percutaneous kidney biopsy 2 days after admission. Light microscopic observation revealed that the specimen contained 31 glomeruli, 10 of which showed global sclerosis. Three glomeruli showed segmental sclerosis with hyperplasia of podocytes and intracapillary marked infiltration of intraglomerular foam cells. These findings were compatible with FSGS, cellular variant (Fig. 1a-c) . Characteristic findings of diabetic glomerulosclerosis or monoclonal gammopathy were not observed, although mildto-moderate interstitial fibrosis with tubular atrophy, and arteriosclerosis were observed. Based on electron microscopy, foam cells containing bubbled lipid droplets were observed in the glomeruli, but there were no electron-dense deposits (Fig. 1c) . In addition, the lipoprotein thrombus 
Phenotypic, genotypic and DNA sequencing analyses of apoE
Since the serum apoE level exceeded the normal range, apoE phenotypes were analyzed by isoelectric focusing polyacrylamide gel electrophoresis, as previously described [4, 5] . Different from apoE3/3 (a wild-type control), the apoE3/5 phenotype was detected in the patient (Fig. 2a) .
We obtained written informed consent for a genomic analysis. The apoE genotype was determined by a restriction fragment length polymorphism (RFLP) analysis, as described previously [4] . Genomic DNA was amplified by polymerase chain reaction (PCR) using oligonucleotide primers (sense 5′-ACG CGG GCA CGG CTG TCC AA-GGA-3′ and antisense 5′-TCG CGG GCC CCG GCC TGG TACAC-3′). The PCR products were digested with the restriction enzyme HhaI. Genotype ε3/3 in the patient was identified by 91-and 48-bp fragments (Fig. 2b) , and other major isoforms, apoE2 (Arg158Cys) and apoE4 (Cys112Arg), were excluded.
Sequencing of APOE DNA was performed as follows. Three fragments of genomic DNA containing the coding sequence of mature APOE were amplified by PCR using the following primers for APOE: 5′-GCT TTC CAA GTG ATT AAA CCG ACT -3′ and 5′-AGA GCT AAA GCC AGG AGT CAG-3′ for exon 3, and 5′-CCT CTT GGG TCT CTC TGG CT-3′, 5′-CTG CTC CTT CAC CTC GTC CA-3′, 5′-GCA GTA CCG CGG CGA GGT GCAGG-3′, and 5′-GAT CGT GCC ACT GCA CTC TA-3′ for exon 4. Amplified DNA fragments were purified using a PCR Purification Kit (Qiagen, Hilden, Germany) and directly sequenced using a Genetic Analyzer 3130xl (Thermo Fisher Scientific, Waltham, MA, USA) with a BigDye Terminator Cycle Sequencing Kit (Thermo Fisher Scientific). A substitution of lysine with glutamic acid at codon 3 of APOE corresponded to the point mutation of heterozygous apoE5 (Glu3Lys), a rare apoE isoform (Fig. 2c) Unfortunately, since his parents had died and their apo E could not be analyzed, it was unclear whether apoE5 mutation was de novo or hereditary.
Clinical course
Based on the kidney biopsy findings, phenotype, and DNA sequence analyses of APOE, we diagnosed the patient to have FSGS with heterozygous apoE5/3. The patient continued taking an angiotensin receptor blocker and HMGCoA reductase inhibitor. Renal function was stable with nephrotic syndrome for 1 year. Both GAG (glutamine; wild type) and AAG (lysine) were observed at codon 3 in exon 3 of apoE, indicating that the apoE (Glu3Lys) alleles were heterozygous Discussion ApoE5 (Glu3Lys) is involved in hyperlipidemia, despite having twofold greater LDL receptor-binding activity than that of normal apoE3. To explain this paradox, it is hypothesized that the enhanced metabolism of apoE5-containing lipoproteins results in hyperlipoproteinemia via the down-regulation of LDL receptors [2, 3] ; however, the precise mechanism is still unclear. A few cases of LPG associated with apoE5 (Glu3Lys) have been reported, but apoE variants specific to LPG, e.g., apoE-Chicago [4] and apoE-Sendai [5] , were also detected in these cases, and the specific role of apoE (Glu3Lys) is unknown.
With respect to the onset of FSGS, dyslipidemia [7] and apoE abnormalities [8] also influence the foamy change of macrophages and mesangial cells, although various factors associated with podocyte injury are important. The role of macrophages in FSGS with hyperlipidemia have been demonstrated experimentally [9] and clinically [10] by Saito and coworkers. In the current case, it is noteworthy that apoE5 (Glu3Lys) results from a single mutation in APOE. Since apoE5 (Glu3Lys) is involved in hyperlipoproteinemia [2, 3] , the mechanism via lipid abnormalities derived from apoE5 as described above may play a pivotal role in the development of FSGS.
The patient was previously treated for diabetes mellitus by a local practitioner, but the diabetic condition was mild, as evidenced by the relatively low blood sugar and HbA1c levels and lack of retinopathy and neuropathy. In addition, MGUS was diagnosed by immunoelectrophoresis and bone marrow aspiration, but characteristic findings of MGUS-related nephropathy were not observed by renal biospy. Therefore, hyperlipoproteinemia related to apoE5 (Glu3Lys) may be involved in the renal injury in this case.
ApoE combined with triglycerides and cholesterol forms lipoproteins and plays a central role in lipoprotein metabolism [11] . Homozygotic E2 glomerulopathy and LPG are representative renal diseases induced by apoE mutations, e.g., homozygous E2 (Arg158Cys) [12] and various novel heterozygous apoE variants [13] , respectively. The frequency of apoE5 is very low [1] , and there are no reports of kidney disorders related to apoE5, except a few cases of LPG caused by a combination of mutations specific to LPG [4, 5] . Although type III hyperlipoproteinemia or intraglomerular lipoprotein thrombi for the diagnosis of LPG was not observed in this case, the risk of hyperlipidemia due to apoE5 may induce various kinds of kidney diseases, similar to other apoE mutations.
In conclusion, we presented a case of FSGS with apoE5 (Glu3Lys), a rare isoform of apoE. The patient's apoE phenotype was apoE5/3. This is the first case report of the development of nephropathies in a patient who had apoE5 (Glu3Lys), but no other apoE mutations. It is possible that the apoE5 (Glu3Lys) allele plays a pivotal role in the development of FSGS induced by dyslipidemia. However, the precise mechanisms have not been elucidated, and the accumulation of more cases of kidney diseases with spoE5 (Glu3Lys) is required.
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